Primary Mode of Action Is A Primary Focus Of Combo Products Hearing

FDA's recent announcement that it is reconsidering jurisdiction for wound products indicates a problematic shift in the agency's interpretation of "primary mode of action," AdvaMed maintained at a June 24 public hearing to discuss the regulation of combination products containing live cellular components